Breaking News

Transposon Therapeutics Acquires Portfolio of Novel Nucleoside Analogs

Can be targeted toward cancers with newly discovered genetic biomarkers that are present in pancreatic and certain other solid tumors plus hematologic cancers.

Author Image

By: Charlie Sternberg

Associate Editor

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, has acquired PrimeFour Therapeutics’ portfolio of novel nucleoside analogs.   The portfolio encompasses a diverse array of unique molecular analogs. The most advanced lead compounds are nucleosides designed to exploit “synthetic lethality” in cancers with specific genetic profiles. By targeting these geneti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters